Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1130
  • Dowloads 119

Original Research

Open Access

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma

  • H. C. Wagenaar1,2
  • S. Pecorelli3
  • I. Vergote4,*,
  • D. Curran2
  • D. J. Th. Wagener5
  • A. Kobierska6
  • G. Bolis7
  • W. ten Bokkel-Huinink8
  • A. J. Lacave9
  • C. Madronal10
  • M. Forni11
  • C. F. de Oliveira12
  • C. Mangioni13
  • M.A. Nooij14
  • A. Goupi115
  • P. Kerbrat16
  • Ch. Marth17
  • S. Tumolo18
  • M. G. Herben19
  • F. Zanaboni20
  • J.B. Vermorken21

1Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands

2EORTC Data Center, Brussels, Belgium

3Department of Gynecology, Universita di Brescia, Italy

4Department of Gynecologic Oncology, University Hospitals Leuven, Belgium

5Department of Medical Oncology, St. Radboud Academic Hospital, Nijmegen, The Netherlands

6Department of Oncology, Medical University of Gdansk, Poland

7Department of Gynecology, lnstituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

88Department of Oncology, Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands

9Department of Oncology, Hospital General de Asturias, Oviedo, Spain

10Department of Oncology, lnstitut d'Oncologia Corachan, Barcelona, Spain

11Department of Oncology, Hospital Cantonal Universitaire de Geneve, Switzerland

12Department of Gynecology, Hospitais da Universidade de Coimbra, Portugal

13Department of Obstetrics and Gynecology, Ospedale San Gerardo, Monza, Italy

14Department of Oncology, Leiden University Medical Center, Leiden, The Netherlands

15Department of Oncology, Centre Rene Huguenin, Saint-Cloud, France

16Department of Internal Medicine, Centre Eugene, Marquis, Rennes, France

17Department of Gynecology, Innsbruck Universitiietsklinik, Innsbruck, Austria

18Department of Oncology, Azienda Ospedaliera Santa Maria Degli Angeli, Pordenone, Italy

19Department of Oncology, Sint Antoniushoeve, Leidschendam, The Netherlands

20Department of Oncology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy

21Department of Oncology, University Hospital Antwerp, Edegem, Belgium

DOI: 10.12892/ejgo200103187 Vol.22,Issue 3,May 2001 pp.187-193

Published: 10 May 2001

*Corresponding Author(s): I. Vergote E-mail:

PDF (727.38 kB) View Full-text

Abstract

Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease.

Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days.

Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively.

Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.

Cite and Share

H. C. Wagenaar,S. Pecorelli,I. Vergote,D. Curran,D. J. Th. Wagener,A. Kobierska,G. Bolis,W. ten Bokkel-Huinink,A. J. Lacave,C. Madronal,M. Forni,C. F. de Oliveira,C. Mangioni,M.A. Nooij,A. Goupi1,P. Kerbrat,Ch. Marth,S. Tumolo,M. G. Herben,F. Zanaboni,J.B. Vermorken. Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. European Journal of Gynaecological Oncology. 2001. 22(3);187-193.

URL:

https://www.ejgo.net/articles/10.12892/ejgo200103187

References

[1] Ozols R. F., Schwartz P. E., Eifel P. J.: "Fallopian tube cancer". In: De Vita Jr V. T., Hellman S., Rosenberg S. A.: "Cancer Principies and Practice of Oncology". New York, Lippincott-Raven, 1997, 1534.

[2] Raju K. S., Barker G. H., Wiltshaw E.: "Primary carcinoma of the fallopian tube. Report of 22 cases". Br. J. Obstet. Gynecol., 1981, 88, 1124.

[3] Friedrich M., Villena-Heinsen C., Schweizer J., Hollander M., Stieber M., Schmidt W.: "Primary tubal carcinoma: A retrospective analysis of four cases with a literature review". Eur. J. Gynaecol. Oneal., 1998, 19, 138.

[4] Wolfson A. H., Tralins K. S., Greven K. M. et al.: "Adenocarcinoma of the fallopian tube: Results of a multi-institutional retrospective analysis of 72 patients". Int. J. Radial. Oneal. Biol. Phys., 1998, 40, 71.

[5] Podratz K. C., Podczaski E. S., Gaffey Th. A., O'Brien P. C., Schray M. F., Malkasian G.D.: "Primary carcinoma of the fallopian tube".Am. J. Gynecol. Obstet., 1986, 154, 1319.

[6] McMurray E. H., Jacobs A. J., Perez C. A., Camel H. M., Kao M. S., Galakatos A.: "Carcinoma of the fallopian tube. Management and sites of failure". Cancer, 1986, 58, 2070.

[7] Eddy G. L., Copeland L. J., Gershenson D. M., Atkinson E. N., Wharton J. T., Rutledge F. N.: "Fallopian tube carcinoma". Obstet Gynecol., 1984, 64, 546.

[8] Denham J. W., MacLennan K. A.: "The management of primary carcinoma of the fallopian tube. Experience of 40 cases". Cancer, 1984, 53, 166.

[9] Cormio G., Maneo A., Gabriele A., Zanetta G., Losa G., Lissoni A.: "Treatment of fallopian tube carcinoma with cyclophospha mide, adriamycin, and cisplatin". Am. J. Clin. Oneal., 1997, 20, 143

[10] Pectasides D., Barbounis V., Sintila A., Varthalitis I., Dimitriadis M., Athanassiou A.: "Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy". Am. J. Clin. Oneal., 1994, 17, 68.

[11] Muntz H. G., Tarraza H. M., Goff B. A. et al.: "Combination chemotherapy in advanced adenocarcinoma of the fallopian tube". Gynecol. Oncol., 1991, 40, 268.

[12] Morris M., Gershenson D. M., Burke Th. W., Kavanagh J. J., Silva E. G., Wharton J. T.: "Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide". Obstet. Gynecol., 1990, 76, 1020.

[13] Peters W. A., Andersen W. A., Hopkins M. P.: "Results of chemotherapy in advanced carcinoma of th.e fallopian tube". Cancer, 1989, 63, 836.

[14] Maxson W. Z., Stehman F. B., Ulbright T. M., Sutton G. P., Ehrlich C. E.: "Primary carcinoma of the fallopian tube: Evidence of activity of cisplatin combination chemotherapy". Gynecol. Oncol., 1987, 26, 305.

[15] Barakat R. R., Rubin S. C., Saigo P. E. et al.: "Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube" Gynecol. Oncol., 1991, 42, 156.

[16] Jacobs A. J., McMurray E. H., Parham J. et al.: "Treatment of carcinoma of the fallopian tube using cisplatin, doxorubicin, and cyclophosphamide". Am. J. Clin. Oncol., 1986, 9, 436.

[17] Omura G., Blessing J. A., Ehrlich C. E. et al.: "A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study". Cancer, 1986, 57, 1725.

[18] Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. The Ovarian Cancer Meta-Analysis Project". J. Clin. Oncol., 1991, 9, 1668.

[19] De Oliveira C. F., Lacave A. J., Villani C. et al.: "Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). An EORTC Gynecological Cancer Cooperative Group Study". Eur. J. Gynaecol. Oncol., 1990, 11, 323.

[20] Miller A. B., Hoogstraten B., Staquet M., Winkler A.: "Reporting results of cancer treatment". Cancer, 1981, 47, 207.

[21] Dodson M. G., F ord J. H. Jr., Averette H. E.: "Clinical aspects of fallopian tube carcinoma". Obstet. Gynecol., 1970, 36, 935.

[22] Gehan E. A.: "The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapy agent". J. Chron. Dis., 1961, 13, 346.

[23] Kaplan E. L., Meier P.: "Nonparametric estimation from incomplete observations". J. Am. Statist. Ass., 1958, 53, 457.

[24] Rose P. G.,P iver M. S.,T sukada Y.: "Fallopian tube cancer. The Rosewell Park Experience". Cancer, 1990, 66, 2661.

[25] Nappi R., Resta L., Nappi L., Loizzi P.: "Primary carcinoma of the fallopian tube: Report on two cases". Eur. J. Obstet. Gynecol Reprod. Biol., 1996, 70, 93.

[26] Deppe G., Bruckner H. W., Cohen C. J.: "Combination chemotherapy for advanced carcinoma of the fallopian tube". Obstet Gynecol., 1980, 56, 530.

[27] Rosen A. C., Klein M., Hafner E. et al.: "Management and prognosis of primary fallopian tube carcinoma". Gynecol. Obstet Invest., 1999, 47, 45.

[28] Rauthe G., Vahrson H. W., Burkhardt E.: "Primary cancer of the fallopian tube. Treatment and results of 37 cases". Eur. J. Gynaecol. Oncol., 1998, 19, 356.

[29] Wang P. H., Yuan C. C., Chao H. T., Juang C. M., Ng H. T.: "Prognosis of primary fallopian tube adenocarcinoma: Report of 25 patients". Eur. J. Gynaecol. Oncol., 1998, 19, 571.

[30] Klein M., Rosen A., Lahousen M. et al.: "Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube". Arch. Gynecol. Obstet., 1994, 255, 19.

Abstracted / indexed in

Web of Science (WOS) (On Hold)

Journal Citation Reports/Science Edition

Google Scholar

JournalSeek

Submission Turnaround Time

Top